Academic Perspectives on Systemic Therapy for Advanced uHCC
An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy through imaging, α-fetoprotein levels, and tolerability. Treatment decisions are guided by response assessment, adverse events, and liver function. First-line (1L) options include tyrosine kinase inhibitors and immunotherapy combinations, with promising trials exploring novel immune combinations and targeted approaches that may reshape the treatment landscape.
Video Player is loading.
Video content above is prompted by the following:
- What remaining clinical pearls can you share regarding systemic therapy treatment approaches for patients with advanced uHCC?
- How do you evaluate treatment success over time, and what are key indicators that guide decisions regarding treatment modifications or sequencing?
- What trials are you anticipating that might affect the 1L treatment of uHCC?
Recent Videos
COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application
Clinical Impact of COCOON: Advancing Dermatologic AE Management
Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
